Drug Profile


Alternative Names: CP 66248; CP 66248 2; Enable; Enablex® - Rheumatoid arthritis; Kenida®; Reumaten; Tenedac

Latest Information Update: 25 Mar 1998

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Developer Pfizer; Roerig
  • Class Anti-inflammatories; Antirheumatics; Indoles
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued HIV infections; Osteoarthritis; Rheumatoid arthritis

Most Recent Events

  • 25 Mar 1998 Discontinued-Preregistration for Osteoarthritis in USA (PO)
  • 30 Jan 1998 Discontinued-I for HIV infections treatment in USA (Unknown route)
  • 05 Dec 1997 Data have been added to the Therapeutic Trials and Adverse Events sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top